Acute leukemias in children with Down syndrome.

[1]  Sharon R. Pine,et al.  Incidence and clinical implications of GATA1 mutations in newborns with Down syndrome. , 2007, Blood.

[2]  S. Izraeli,et al.  Trisomy of chromosome 21 in leukemogenesis. , 2007, Blood cells, molecules & diseases.

[3]  P. Vyas,et al.  Analysis of JAK3, JAK2, and C-MPL mutations in transient myeloproliferative disorder and myeloid leukemia of Down syndrome blasts in children with Down syndrome. , 2007, Blood.

[4]  P. Vyas,et al.  Severe TMD/AMKL with GATA1 mutation in a stillborn fetus with Down syndrome , 2007, Nature Clinical Practice Oncology.

[5]  D. Reinhardt,et al.  Janus kinase mutations in the development of acute megakaryoblastic leukemia in children with and without Down's syndrome , 2007, Leukemia.

[6]  D. Reinhardt,et al.  Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AML , 2007, Pediatric blood & cancer.

[7]  D. Nižetić,et al.  Loss‐of‐function JAK3 mutations in TMD and AMKL of Down syndrome , 2007, British journal of haematology.

[8]  P. Vyas,et al.  Molecular insights into Down syndrome-associated leukemia , 2007, Current opinion in pediatrics.

[9]  T. Naoe,et al.  JAK3 mutations occur in acute megakaryoblastic leukemia both in Down syndrome children and non-Down syndrome adults , 2007, Leukemia.

[10]  P. Vyas,et al.  Down myeloid disorders: a paradigm for childhood preleukaemia and leukaemia and insights into normal megakaryopoiesis. , 2006, Early human development.

[11]  J. Whitlock.  Down syndrome and acute lymphoblastic leukaemia , 2006, British journal of haematology.

[12]  R. Arceci,et al.  Outcome of Down Syndrome (DS) Children with Acute Myeloid Leukemia (AML) or Myelodysplasia (MDS) Treated with a Uniform Prospective Clinical Trial - Initial Report of the COG Trial A2971. , 2006 .

[13]  Y. Ravindranath,et al.  Excessive Cardiotoxicity Despite Excellent Leukemia-Free Survival for Pediatric Patients with Down Syndrome (DS) and Acute Myeloid Leukemia (AML): Results from POG (Pediatric Oncology Group) Protocol 9421. , 2006 .

[14]  P. Vyas,et al.  Trisomy 21 expands the megakaryocyte-erythroid progenitor compartment in human fetal liver-implications for down syndrome AMKL. , 2006 .

[15]  Sandra A. Moore,et al.  JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model. , 2006, Blood.

[16]  D. Reinhardt,et al.  Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  A. F. Cunha,et al.  An inherited mutation leading to production of only the short isoform of GATA-1 is associated with impaired erythropoiesis , 2006, Nature Genetics.

[18]  Sandra A. Moore,et al.  Activating alleles of JAK3 in acute megakaryoblastic leukemia. , 2006, Cancer cell.

[19]  A. Zipursky,et al.  Long‐term results of an ultra low‐dose cytarabine‐based regimen for the treatment of acute megakaryoblastic leukaemia in children with Down syndrome , 2006, British journal of haematology.

[20]  H. Hasle,et al.  WT1 gene expression in children with Down syndrome and transient myeloproliferative disorder. , 2006, Leukemia research.

[21]  G. Gustafsson,et al.  Optimal treatment intensity in children with Down syndrome and myeloid leukaemia: data from 56 children treated on NOPHO-AML protocols and a review of the literature , 2006, Annals of Hematology.

[22]  Aravind Subramanian,et al.  Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[23]  M. Caligiuri,et al.  Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  N. Heerema,et al.  Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: a Children's Cancer Group study. , 2005, Blood.

[25]  W. Hop,et al.  Intrinsic abnormalities of lymphocyte counts in children with down syndrome. , 2005, The Journal of pediatrics.

[26]  Sharon R. Pine,et al.  GATA1 as a new target to detect minimal residual disease in both transient leukemia and megakaryoblastic leukemia of Down syndrome. , 2005, Leukemia research.

[27]  P. Vyas,et al.  GATA1-Mediated Megakaryocyte Differentiation and Growth Control Can Be Uncoupled and Mapped to Different Domains in GATA1 , 2005, Molecular and Cellular Biology.

[28]  B. Göttgens,et al.  The proto-oncogene ERG in megakaryoblastic leukemias. , 2005, Cancer research.

[29]  J. Crispino,et al.  Differential requirements for the activation domain and FOG-interaction surface of GATA-1 in megakaryocyte gene expression and development. , 2005, Blood.

[30]  D. Reinhardt,et al.  AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity , 2005, Leukemia.

[31]  A. Cantor.  GATA Transcription Factors in Hematologic Disease , 2005, International journal of hematology.

[32]  S. Orkin,et al.  Developmental stage–selective effect of somatically mutated leukemogenic transcription factor GATA1 , 2005, Nature Genetics.

[33]  G. Gustafsson,et al.  Acute leukaemia in children with Down syndrome: a population‐based Nordic study , 2005, British journal of haematology.

[34]  N. Heerema,et al.  Lymphoblast biology and outcome among children with Down syndrome and ALL treated on CCG‐1952 , 2005, Pediatric blood & cancer.

[35]  M. König,et al.  EQUAL FREQUENCY OF TEL/AML1 REARRANGEMENTS IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA WITH AND WITHOUT DOWN SYNDROME , 2005, Pediatric hematology and oncology.

[36]  J. Taub,et al.  Down syndrome, drug metabolism and chromosome 21 , 2005, Pediatric blood & cancer.

[37]  A. Gamis.  Acute myeloid leukemia and Down Syndrome evolution of modern therapy—state of the art review , 2005, Pediatric blood & cancer.

[38]  J. Taub,et al.  Prenatal origin of GATA1 mutations may be an initiating step in the development of megakaryocytic leukemia in Down syndrome. , 2004, Blood.

[39]  P. Vyas,et al.  Natural history of GATA1 mutations in Down syndrome. , 2004, Blood.

[40]  Y. Ravindranath,et al.  The Role of Cytidine Deaminase and GATA1 Mutations in the Increased Cytosine Arabinoside Sensitivity of Down Syndrome Myeloblasts and Leukemia Cell Lines , 2004, Cancer Research.

[41]  Y. Hayashi,et al.  Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndrome. , 2003, Blood.

[42]  Y. Ravindranath.  Down syndrome and acute myeloid leukemia: the paradox of increased risk for leukemia and heightened sensitivity to chemotherapy. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  T. Alonzo,et al.  Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children's Cancer Group Study 2891. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  A. Teigler‐Schlegel,et al.  Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21. , 2003, Blood.

[45]  S. Scherer,et al.  GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome. , 2003, Blood.

[46]  R. Arceci,et al.  Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis. , 2003, Blood.

[47]  D. Nižetić,et al.  Acquired mutations in GATA1 in neonates with Down's syndrome with transient myeloid disorder , 2003, The Lancet.

[48]  N. Roizen,et al.  Down's syndrome , 2003, The Lancet.

[49]  I. Baumann,et al.  A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases , 2003, Leukemia.

[50]  N. Harris,et al.  The World Health Organization (WHO) classification of the myeloid neoplasms. , 2002, Blood.

[51]  M. L. Beau,et al.  Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome , 2002, Nature Genetics.

[52]  H. Kempski,et al.  Clinical features, cytogenetics and outcome in acute lymphoblastic and myeloid leukaemia of infancy: report from the MRC Childhood Leukaemia working party , 2002, Leukemia.

[53]  K. Deguchi,et al.  Cooperativity between mutations in tyrosine kinases and in hematopoietic transcription factors in AML , 2002, Leukemia.

[54]  A. Zipursky,et al.  Incidence and Treatment of Potentially Lethal Diseases in Transient Leukemia of Down Syndrome: Pediatric Oncology Group Study , 2002, Journal of pediatric hematology/oncology.

[55]  R. Hanada,et al.  Distinctive Multidrug Sensitivity and Outcome of Acute Erythroblastic and Megakaryoblastic Leukemia in Children With Down Syndrome , 2001, International journal of hematology.

[56]  R. Mohammad,et al.  Cystathionine-beta-synthase cDNA transfection alters the sensitivity and metabolism of 1-beta-D-arabinofuranosylcytosine in CCRF-CEM leukemia cells in vitro and in vivo: a model of leukemia in Down syndrome. , 2000, Cancer research.

[57]  G. Gustafsson,et al.  Cellular cytotoxic drug sensitivity in children with acute leukemia and Down's syndrome: an explanation to differences in clinical outcome? , 2000, Leukemia.

[58]  H. Hasle,et al.  Risks of leukaemia and solid tumours in individuals with Down's syndrome , 2000, The Lancet.

[59]  Y. Ravindranath,et al.  Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin. , 1999, Blood.

[60]  J. Harbott,et al.  Down’s syndrome in childhood acute lymphoblastic leukemia: clinical characteristics and treatment outcome in four consecutive BFM trials , 1998, Leukemia.

[61]  J. Buckley,et al.  Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group Studies 2861 and 2891. , 1998, Blood.

[62]  Y. Ravindranath,et al.  Myeloblasts from Doen syndrome children with acute myeloid leukemia have increased in vitro sensitivity to cytosine arabinoside and daunorubicine , 1997, Leukemia.

[63]  G. Basso,et al.  The common TEL/AML1 rearrangement does not represent a frequent event in acute lymphoblastic leukaemia occurring in children with Down syndrome , 1997, Leukemia.

[64]  J. Harbott,et al.  Myelodysplasia and acute myelogenous leukemia in Down's syndrome. A report of 40 children of the AML-BFM Study Group. , 1996, Leukemia.

[65]  M. Siimes,et al.  A population‐based study of 272 children with acute myeloid leukaemia treated on two consecutive protocols with different intensity: best outcome in girls, infants, and children with Down's syndrome , 1996 .

[66]  J. Gurney,et al.  Enhanced metabolism of 1-beta-D-arabinofuranosylcytosine in Down syndrome cells: a contributing factor to the superior event free survival of Down syndrome children with acute myeloid leukemia. , 1996, Blood.

[67]  M. Siimes,et al.  Peripheral blood cell counts in infants with Down's syndrome , 1996, Clinical genetics.

[68]  S. Raimondi,et al.  Immunophenotypes and karyotypes of leukemic cells in children with Down syndrome and acute lymphoblastic leukemia. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  J. Krischer,et al.  Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498. , 1992, Blood.

[70]  M. Relling,et al.  Pharmacokinetics and toxicity of methotrexate in children with Down syndrome and acute lymphocytic leukemia. , 1987, The Journal of pediatrics.

[71]  R. Good,et al.  The simultaneous occurrence of leukemia and mongolism; report of four cases. , 1956, A.M.A. journal of diseases of children.

[72]  M. Weijerman,et al.  Prevalence, neonatal characteristics, and first-year mortality of Down syndrome: a national study. , 2008, The Journal of pediatrics.

[73]  R. Christensen,et al.  Hematological abnormalities during the first week of life among neonates with Down syndrome: Data from a multihospital healthcare system , 2007, American journal of medical genetics. Part A.

[74]  S. Nasim,et al.  A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children’s Oncology Group (COG) study POG-9481 , 2006 .

[75]  F. Behm,et al.  children with AML in remission : Pediatric Oncology Group Study 9421 Randomized use of cyclosporin A ( CsA ) to modulate P-glycoprotein in , 2005 .

[76]  A. Zipursky,et al.  Origins of leukaemia in children with Down syndrome , 2005, Nature Reviews Cancer.

[77]  M. Greaves.  In utero origins of childhood leukaemia. , 2005, Early human development.

[78]  Y. Hayashi,et al.  Fetal origin of the GATA1 mutation in identical twins with transient myeloproliferative disorder and acute megakaryoblastic leukemia accompanying Down syndrome. , 2004, Blood.

[79]  G. Peters,et al.  Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome. , 2002, Blood.

[80]  J. Widness,et al.  Elevated erythropoietin levels in cord blood of newborns with Down's syndrome. , 1994, Biology of the neonate.